Gastrointestinal Stromal Tumor
Gastrointestinal stromal tumor apoptosis induced by flavopiridol
Published in Cancer Weekly, August 8th, 2006
According to a study from the United States, "GIST are characterized by activating mutations in the c-KIT gene which confers ligand-independent activation of the KIT receptor. Imatinib mesylate has been shown to effectively block constitutively active KIT and delay tumor growth. However, resistance to imatinib mesylate is emerging as a major clinical problem and novel therapies are needed."
"We report that treatment of GIST cells with the transcriptional inhibitor flavopiridol, initially down-regulates the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-08-08)
More Articles from Cancer Weekly
- Cancer Registries
Period estimates of cancer patient survival deemed more up-to-date than complete estimates - Diagnostics
Modified nucleosides and creatinine in urine samples used in early cancer detection - Diet & Nutrition
Consumption advisories of farmed salmon based on cancer risk reported - Prostate Cancer
Prostate cancer risk in African American men linked to common nonsense mutation in EphB2 - Adrenocortical Cancer
Adrenocortical carcinoma management depends on better understanding of molecular pathogenesis - Anal Cancer
Anal cancer responded to mitomycin-C, adriamycin, cisplatin and bleomycin-CCNU - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
